Side Hu

Asparaginyl endopeptidases (AEPs) are cysteine proteases which break Asx (Asn/Asp)–Xaa bonds in acidic conditions. Despite sharing a conserved overall structure with AEPs, certain plant enzymes such as butelase 1 act as a peptide asparaginyl ligase (PAL) and catalyze Asx–Xaa bond formation in near-neutral conditions. PALs also serve as macrocyclases in the biosynthesis of cyclic peptides. Here, we address the question of how a PAL can function as a ligase rather than a protease. Based on sequence homology of butelase 1, we identified AEPs and PALs from the cyclic peptide-producing plants Viola yedoensis ( Vy ) and Viola canadensis ( Vc ) of the Violaceae family. Using a crystal structure of a PAL obtained at 2.4-Å resolution coupled to mutagenesis studies, we discovered ligase-activity determinants flanking the S1 site, namely LAD1 and LAD2 located around the S2 and S1′ sites, respectively, which modulate ligase activity by controlling the accessibility of water or amine nucleophile to the S -ester intermediate. Recombinantly expressed Vy PAL1–3, predicted to be PALs, were confirmed to be ligases by functional studies. In addition, mutagenesis studies on Vy PAL1–3, Vy AEP1, and Vc AEP supported our prediction that LAD1 and LAD2 are important for ligase activity. In particular, mutagenesis targeting LAD2 selectively enhanced the ligase activity of Vy PAL3 and converted the protease Vc AEP into a ligase. The definition of structural determinants required for ligation activity of the asparaginyl ligases presented here will facilitate genomic identification of PALs and engineering of AEPs into PALs.

Peptide asparaginyl ligases (PALs) catalyze transpeptidation at the Asn residue of a short Asn-Xaa1-Xaa2 tripeptide motif. Due to their high catalytic activity toward the P1-Asn substrates at around neutral pH, PALs have been used extensively for peptide ligation at asparaginyl junctions. PALs also bind to aspartyl substrates, but only when the γCOOH of P1-Asp remains in its neutral, protonated form, which usually requires an acidic pH. However, this limits the availability of the amine nucleophile and, consequently, the ligation efficiency at aspartyl junctions. Because of this perceived inefficiency, the use of PALs for Asp-specific ligation remains largely unexplored. We found that PAL enzymes, such as VyPAL2, display appreciable catalytic activities toward P1-Asp substrates at pH 4–5, which are at least 2 orders of magnitude higher than that of sortase A, making them practically useful for both intra- and intermolecular ligations. This also allows sequential ligations, first at Asp and then at Asn junctions, because the newly formed aspartyl peptide bond is resistant to the ligase at the pH used for asparaginyl ligation in the second step. Using this pH-controlled orthogonal ligation method, we dually labeled truncated sfGFP with a cancer-targeting peptide and a doxorubicin derivative at the respective N- and C-terminal ends in the N-to-C direction. In addition, a fluorescein tag and doxorubicin derivative were tagged to an EGFR-targeting affibody in the C-to-N direction. This study shows that the pH-dependent catalytic activity of PAL enzymes can be exploited to prepare multifunction protein biologics for pharmacological applications.

Butelase-1 is a peptide asparaginyl ligase (PAL) that efficiently catalyzes peptide bond formation after Asn/Asp (Asx), whereas its homologue butelase-2 is an asparaginyl endopeptidase (AEP) that catalyzes the reverse reaction, hydrolyzing Asx-peptide bonds. Since PALs and AEPs share essentially similar overall structures, we surmised that the S2 and S1′ substrate-binding pockets immediately flanking the catalytic S1 site constitute the major ligase activity determinants (LADs) that control the catalytic directionality of these enzymes. Here, we report the successful conversion of butelase-2 into butelase-1-like ligases based on the LAD hypothesis. We prepared 23 LAD mutants by mutating residues of the S2 pocket (LAD1) and/or the S1′ pocket (LAD2) of butelase-2 into homologous residues in PALs. These LAD mutants markedly diminished protease activity and increased ligase activity. In contrast, substituting 12 non-LAD residues to the corresponding residues in butelase-1 did not change their protease profiles. At physiological pH, mutations targeting both LADs resulted in shifting the catalytic directionality from 95% hydrolysis to >95% peptide ligation. This results in the engineering of efficient recombinant peptide ligases that were demonstrated to be useful for macrocyclization and site-specific labeling of bioactive peptides and proteins. Five high-resolution crystal structures of butelase-2 and its engineered mutants reveal subtle changes proximal to the catalytic S1 site that account for the reversal in enzymatic activity. Computational simulations of enzyme–substrate complexes suggest how the S-acyl intermediate is positioned at the S2 site and the substrate orientated, controlling accessibility of either water or incoming nucleophiles from the prime-side (S1′ site) of the catalytic center. Together, these features determine the catalytic directionality between hydrolysis and ligation in AEPs and PALs. Overall, this work validates the LAD hypothesis as a central guide for making peptide ligases from their corresponding widely available protease counterparts, to produce precision tools for exquisite site-specific conjugation and the biomanufacturing of biologics.

The last two decades have seen an increasing demand for new protein-modification methods from the biotech industry and biomedical research communities. Owing to their mild aqueous reaction conditions, enzymatic methods based on the use of peptide ligases are particularly desirable. In this regard, the recently discovered peptidyl Asx-specific ligases (PALs) have emerged as powerful biotechnological tools in recent years. However, as a new class of peptide ligases, their scope and application remain underexplored. Herein, we report the use of a new PAL, VyPAL2, for a diverse range of protein modifications. We successfully showed that VyPAL2 was an efficient biocatalyst for protein labelling, inter-protein ligation, and protein cyclization. The labelled or cyclized protein ligands remained functionally active in binding to their target receptors. We also demonstrated on-cell labelling of protein ligands pre-bound to cellular receptors and cell-surface engineering via modifying a covalently anchored peptide substrate pre-installed on cell-surface glycans. Together, these examples firmly establish Asx-specific ligases, such as VyPAL2, as the biocatalysts of the future for site-specific protein modification, with a myriad of applications in basic research and drug discovery.

Enzymatic peptide ligation holds great promise in the study of protein functions and development of protein therapeutics. Owing to their high catalytic efficiency and a minimal tripeptide recognition motif, peptidyl asparaginyl ligases (PALs) are particularly useful tools for bioconjugation. However, as an inherent limitation of transpeptidases, PAL-mediated ligation is reversible, requiring a large excess of one of the ligation partners to shift the reaction equilibrium in the forward direction. Herein, we report a method to make PAL-mediated intermolecular ligation irreversible by coupling it to glutaminyl cyclase (QC)-catalyzed pyroglutamyl formation. In this method, the acyl donor substrate of PALs is designed to have glutamine at the P1′ position of the Asn-P1′-P2′ tripeptide PAL recognition motif. Upon ligation with an acyl acceptor substrate, the acyl donor substrate releases a leaving group in which the exposed N-terminal glutamine is cyclized by QC, quenching the Gln Nα-amine in a lactam. Using this method, PAL-mediated ligation can achieve near-quantitative yields even at an equal molar ratio between the two ligation partners. We have demonstrated this method for a wide range of applications, including protein-to-protein ligations. We anticipate that this cascade enzymatic reaction scheme will make PAL enzymes well suited for numerous new uses in biotechnology.